About Daliscia

At Daliscia, our mission is to revolutionize pharmaceutical manufacturing and research operations through regulatory-compliant generative AI solutions that significantly reduce costs, improve quality, and accelerate time-to-market.

According to McKinsey, generative AI can be a true game-changer for biopharma operations. Our solutions focus on six high-impact areas:

• AI-Generated Lab Protocols - Leveraging AI agents to search scientific literature and generate optimized, GMP-compliant protocols that reduce protocol development time by up to 30% while ensuring consistent quality
• Batch Record Analysis - Extracting critical quality attributes from batch records with 99% accuracy, reducing review time by 40%, and ensuring data integrity for regulatory submissions in compliance with 21 CFR Part 11
• Smart Deviation Management - Reducing deviations by 30-40% through improved prevention and automation, with our solution identifying similar historical deviations, accelerating root cause analysis, and suggesting effective CAPAs
• Shop Floor Efficiency - Empowering manufacturing supervisors with GenAI assistant tools that reduce administrative workload by 40-50%, allowing them to focus on team leadership and process improvement
• Document Digitization & Knowledge Management - Transforming legacy documentation into searchable knowledge repositories, reducing document processing time by 45% and decreasing time spent searching for information by 25%
• Custom GMP-Compliant Solutions - Designing tailored AI solutions for unique operational challenges with our team of industry experts and AI engineers

Through these innovations, we're helping biopharma companies address the 4-6% of manufacturing resources typically dedicated to deviation and CAPA management, while reducing the 65% of drug shortages caused by issues related to deviation management.